Josephine Bagnall

Josephine Bagnall

Auto-generated profile, based on publicly available information

Josephine Bagnall

Infectious Disease and Microbiome Program, Broad Institute of MIT and Harvard, Boston, MA, USA

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2020 in Nature Methods
Verified
Journal Article
Closed access
PDF file
MUMarta Urbanska
Marta Urbanska
HMHector E. Muñoz
Hector E. Muñoz
JBJosephine Shaw Bagnall
Josephine Shaw Bagnall
OOOliver Otto
Oliver Otto
SMScott R. Manalis
Scott R. Manalis
JGJochen Guck
Jochen Guck

28 October 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
KRKeith P. Romano
Keith P. Romano
JBJosephine Bagnall
Josephine Bagnall
TWThulasi Warrier
Thulasi Warrier
JSJaryd Sullivan
Jaryd Sullivan
KFKristina Ferrara
Kristina Ferrara
DHDeborah T. Hung
Deborah T. Hung
The rising prevalence of antibiotic resistance threatens human health. While more sophisticated strategies for antibiotic discovery are being developed, target elucidation of new chemical entities remains challenging. In the postgenomic era, expression profiling can play an important role in mechanism-of-action (MOA) prediction by reporting on the cellular response to perturbation. However, the broad application of transcriptomics has yet to fulfill its promise of transforming target elucidation due to challenges in identifying the most relevant, direct responses to target inhibition. We developed an unbiased strategy for MOA prediction, called perturbation-specific transcriptional mapping (PerSpecTM), in which large-throughput expression profiling of wild-type or hypomorphic mutants, depleted for essential targets, enables a computational strategy to address this challenge. We applied PerSpecTM to perform reference-based MOA prediction based on the principle that similar perturbations, whether chemical or genetic, will elicit similar transcriptional responses. Using this approach, we elucidated the MOAs of three molecules with activity against Pseudomonas aeruginosa by comparing their expression profiles to those of a reference set of antimicrobial compounds with known MOAs. We also show that transcriptional responses to small-molecule inhibition resemble those resulting from genetic depletion of essential targets by clustered regularly interspaced short palindromic repeats interference (CRISPRi) by PerSpecTM, demonstrating proof of concept that correlations between expression profiles of small-molecule and genetic perturbations can facilitate MOA prediction when no chemical entities exist to serve as a reference. Empowered by PerSpecTM, this work lays the foundation for an unbiased, readily scalable, systematic reference-based strategy for MOA elucidation that could transform antibiotic discovery efforts.

28 April 2024 in bioRxiv
Verified
Preprint
Open access
PDF file
KRKeith P Romano
Keith P Romano
JBJosephine Bagnall
Josephine Bagnall
TWThulasi Warrier
Thulasi Warrier
JSJaryd Sullivan
Jaryd Sullivan
KFKristina Ferrara
Kristina Ferrara
DHDeborah T Hung
Deborah T Hung
The rising prevalence of antibiotic resistance threatens human health. While more sophisticated strategies for antibiotic discovery are being developed, target elucidation of new chemical entities remains challenging. In the post-genomic era, expression profiling can play an important role in mechanism-of-action (MOA) prediction by reporting on the cellular response to perturbation. However, the broad application of transcriptomics has yet to fulfill its promise of transforming target elucidation due to challenges in identifying the most relevant, direct responses to target inhibition. We developed an unbiased strategy for MOA prediction, called Perturbation-Specific Transcriptional Mapping (PerSpecTM), in which large-throughput expression profiling of wildtype or hypomorphic mutants, depleted for essential targets, enables a computational strategy to address this challenge. We applied PerSpecTM to perform reference-based MOA prediction based on the principle that similar perturbations, whether chemical or genetic, will elicit similar transcriptional responses. Using this approach, we elucidated the MOAs of three new molecules with activity against Pseudomonas aeruginosa by comparing their expression profiles to those of a reference set of antimicrobial compounds with known MOAs. We also show that transcriptional responses to small molecule inhibition resemble those resulting from genetic depletion of essential targets by CRISPRi by PerSpecTM, demonstrating proof-of-concept that correlations between expression profiles of small molecule and genetic perturbations can facilitate MOA prediction when no chemical entities exist to serve as a reference. Empowered by PerSpecTM, this work lays the foundation for an unbiased, readily scalable, systematic reference-based strategy for MOA elucidation that could transform antibiotic discovery efforts. Significance Statement: New antibiotics are critically needed in the face of increasing antibiotic resistance. However, mechanism-of-action (MOA) elucidation remains challenging and imposes a major bottleneck in antibiotic discovery and development. Building on the principle that molecules with similar MOAs elicit similar transcriptional responses, we have developed a highly scalable strategy for MOA prediction in the important bacterial pathogen Pseudomonas aeruginosa based on correlations between the expression profiles of new molecules and known perturbations, either small molecule inhibition by known antibiotics or transcriptional repression of essential targets by CRISPRi. By rapidly assigning MOAs to three new molecules with anti-pseudomonal activity, we provide proof-of-concept for a rapid, comprehensive, systematic, reference-based approach to MOA prediction with the potential to transform antibiotic discovery efforts.

2 October 2026 in Science Advances
Verified
Journal Article
Closed access
DRDavid J. Roach
David J. Roach
BSBhrus Pun Sangruji
Bhrus Pun Sangruji
SBShriya Bhat
Shriya Bhat
STSelama Tesfamariam
Selama Tesfamariam
IBIshay Ben-Zion
Ishay Ben-Zion
RBRoby P. Bhattacharyya
Roby P. Bhattacharyya
Antimicrobial resistance is a major global health threat, with disproportionate impact in regions with limited diagnostic infrastructure. To address this challenge, we developed BADLOCK (Bacterial and AMR Detection by SHERLOCK), a rapid, low-cost molecular diagnostic platform for direct detection of bacterial pathogens and resistance genes from clinical samples. BADLOCK operates as a one-pot CRISPR-Cas13a reaction capable of detecting nine bacterial species and four major resistance genes directly from positive blood culture. It requires only a heat block and a basic fluorometer for operation. We validated BADLOCK on 194 sequentially collected clinical blood culture specimens growing Gram-negative rods, supplemented with 69 mock samples generated from banked isolates enriched for targeted resistance genes. In all, we conducted 2224 individual reactions, achieving 97.6% accuracy (2171 of 2224) at the reaction level. At the assay level, 89.5% (274 of 306) showed perfect or partial concordance with gold-standard species and resistance gene detection, including 255 assays with perfect concordance and 19 with partial concordance (correct detection of at least one pathogen). This included an evaluation of BADLOCK as a potential culture-free diagnostic for urinary tract infections (UTIs), achieving 98.0% reaction-level accuracy. At the assay level, 95.3% (41 of 43) were partially or perfectly concordant with gold-standard detection of both species and resistance genes. To our knowledge, this represents the first demonstration of the CRISPR-Cas13a diagnostic platform on clinical bloodstream infections to date and supports BADLOCK’s potential as a practical and scalable solution for rapid pathogen and resistance gene detection in resource-constrained settings.